8-K: Alto Neuroscience Announces Positive Interim Analysis for ALTO-300 Phase 2b Depression Trial

Alto Neuroscience reports a favorable outcome from the interim analysis of its ALTO-300 Phase 2b trial for major depressive disorder, leading to a continuation of the study with an increased target patient population.

Summary

• Alto Neuroscience announced a favorable outcome from the interim analysis of its Phase 2b trial of ALTO-300 for major depressive disorder (MDD).
• The interim analysis recommends continuing the study with a target of approximately 200 biomarker-positive patients in the final analysis sample.
• Topline results from the trial are expected in mid-2026.
• The company estimates a preliminary year-end 2024 cash balance of approximately $168 million, which is expected to support operations into 2028.
• The Phase 2b trial is a double-blind, placebo-controlled study enrolling patients with an electroencephalogram (EEG) biomarker signature.
• Patients are randomized to receive ALTO-300 or placebo in addition to a background antidepressant over a six-week treatment period.
• The primary outcome is the change from baseline on the Montgomery-sberg Depression Rating Scale (MADRS) score.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the favorable outcome of the interim analysis and the company's strong cash position. However, the inherent risks associated with clinical trials and the uncertainty of future results temper the overall sentiment.

Positives

• The favorable outcome from the interim analysis of the ALTO-300 Phase 2b trial is a positive development.
• The company's estimated $168 million cash balance is expected to support operations into 2028, providing financial stability.
• The continuation of the trial with an increased patient population suggests confidence in the drug's potential.

Risks

• The actual financial results for 2024 may differ materially from the preliminary estimate.
• The success of the trial is not guaranteed, and topline results in mid-2026 may not be favorable.
• Clinical trials may have unsatisfactory outcomes.
• The company's projections regarding its financial position and expected cash runway may be inaccurate or its conduct of its business requires more cash than anticipated.

Future Outlook

The company expects to report topline data from the ALTO-300 Phase 2b trial in mid-2026 and believes its current cash balance will support operations into 2028.

Management Comments

• Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neuroscience, stated that the interim analysis outcome marks an important milestone for the ALTO-300 program.
• He also mentioned that the interim analysis leveraged valuable insight from the completed ALTO-100 Phase 2b trial.

Industry Context

Alto Neuroscience is focused on developing precision medicines for neuropsychiatric disorders, a growing area of interest in the biopharmaceutical industry. The use of biomarkers to identify patients more likely to respond to treatment is a key aspect of their approach, aligning with the broader trend towards personalized medicine.

Comparison to Industry Standards

• Many companies are developing drugs for MDD, including Sage Therapeutics (Zuranolone) and Axsome Therapeutics (Auvelity).
• Alto's approach of using EEG biomarkers to identify patients who are more likely to respond to ALTO-300 is similar to efforts by other companies to personalize treatment based on genetic or other biomarkers.
• The six-week treatment period in the ALTO-300 trial is a common duration for MDD clinical trials.

Stakeholder Impact

• Positive news for shareholders due to the favorable interim analysis outcome.
• Potential benefit for patients with major depressive disorder if ALTO-300 proves effective.
• Positive impact on employees due to the company's financial stability and continued operations.

Next Steps

• Continue the Phase 2b trial of ALTO-300 with an increased target patient population.
• Enroll approximately 200 biomarker-positive patients in the final analysis sample.
• Report topline data from the trial in mid-2026.

Key Dates

Keywords

ALTO-300, Major Depressive Disorder, MDD, Phase 2b Trial, Interim Analysis, Biomarker, EEG, Neuroscience, Clinical Trial, Depression, ALTO-100